Tubulis Acquired by Gilead Sciences | Healthcare M&A Deal

Gilead Sciences has acquired Tubulis, a healthcare services other business in the United States, for $3.15 billion. Gilead Sciences acquisitions focus on advancing targeted cancer therapies by leveraging Tubulis capabilities in precision oncology and treatment development. Tubulis acquisition supports healthcare M&A strategy by strengthening Gilead’s pipeline and expanding translational research capacity for oncology programs. The merger acquisition is a strategic acquisition by a public biopharma buyer, with deal terms reported at up to $5.0 billion and an announced status.